Vaccinated patients have reduced rates of hospitalization after receiving casirivimab and imdevimab for COVID-19
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:56 |
|---|---|
| Enthalten in: |
The American journal of emergency medicine - 56(2022) vom: 04. Juni, Seite 370-371 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zitek, Tony [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
2Z3DQD2JHM |
|---|
| Anmerkungen: |
Date Completed 20.05.2022 Date Revised 21.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ajem.2021.10.044 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333018559 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333018559 | ||
| 003 | DE-627 | ||
| 005 | 20231225220755.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ajem.2021.10.044 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1110.xml |
| 035 | |a (DE-627)NLM333018559 | ||
| 035 | |a (NLM)34763963 | ||
| 035 | |a (PII)S0735-6757(21)00889-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zitek, Tony |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Vaccinated patients have reduced rates of hospitalization after receiving casirivimab and imdevimab for COVID-19 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.05.2022 | ||
| 500 | |a Date Revised 21.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Casirivimab/imdevimab | |
| 650 | 4 | |a Monoclonal antibodies | |
| 650 | 4 | |a Vaccination | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a imdevimab |2 NLM | |
| 650 | 7 | |a 2Z3DQD2JHM |2 NLM | |
| 650 | 7 | |a casirivimab |2 NLM | |
| 650 | 7 | |a J0FI6WE1QN |2 NLM | |
| 700 | 1 | |a Jodoin, Kathleen |e verfasserin |4 aut | |
| 700 | 1 | |a Kheradia, Tarang |e verfasserin |4 aut | |
| 700 | 1 | |a Napolillo, Ryan |e verfasserin |4 aut | |
| 700 | 1 | |a Dalley, Michael T |e verfasserin |4 aut | |
| 700 | 1 | |a Quenzer, Faith |e verfasserin |4 aut | |
| 700 | 1 | |a Farcy, David A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The American journal of emergency medicine |d 1986 |g 56(2022) vom: 04. Juni, Seite 370-371 |w (DE-627)NLM01297868X |x 1532-8171 |7 nnns |
| 773 | 1 | 8 | |g volume:56 |g year:2022 |g day:04 |g month:06 |g pages:370-371 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ajem.2021.10.044 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 56 |j 2022 |b 04 |c 06 |h 370-371 | ||